Rheb is Overexpressed in Certain Cancers
Posted by WH in News, tags: mTor, oncology, rhebThe mTOR (mammalian target of rapamycin) pathway represents a convergence point for signalling pathways commonly disrupted in cancer. The pathway includes several known and putative oncogenes as well as tumour suppressors. Rheb GTPase is the upstream activator of the mTOR Complex 1 (mTORC1) and is itself activated by growth factors and nutrients.
Two independent papers in the August 15th issue of Genes and Development link Rheb activity with particular cancers. Wendel et. al. demonstrate that Rheb activation can produce rapid development of aggressive and drug-resistant lymphomas. The authors further show that activation of mTORC1 is dependent on farnesylation of Rheb and that an inhibitor of farnesyl transferase (FTI) is able to block the activation. It is noted that Rheb is highly expressed in certain human lymphomas.
Pandolfi et. al. show that overexpression of Rheb promotes hyperplasia and a low-grade neoplastic phenotype in the mouse prostate. Additionally, Rheb overexpression combined with Pten haploinsufficiency results in marked promotion of prostate tumorigenesis.
These results suggest potential for Rheb as a therapeutic target in particular oncology indications.
Related posts:
- AT1 Receptor Linked to Subset of Breast Cancers Increasingly, scientists and doctors are trying to personalise cancer treatment by identifying genetic alterations involved in the disease in individual...
- mTOR Linked to Myelin Repair The axons of nerve cells are sheathed by an insulating layer of myelin which is made up of about 80%...
- Prostate Cancer and NSAID Use Prostate cancer is the most common cancer in men, with the majority of cases occurring in the over-65s. Rising levels...
- Retrovirus Linked to Prostate Cancer A number of human cancers are linked to viral infection including cervical cancer (human papilloma virus), liver cancer (hepatitis B...
- mTORC1 and MAPK Inhibitors for Treatment of Cancer Rapamycin is a macrolide antibiotic used as an immunosuppressant to prevent organ rejection in transplant patients. Rapamycin and analogues have...
Related posts brought to you by Yet Another Related Posts Plugin.
This entry was posted on Thursday, August 21st, 2008 at 8:39 am and is filed under News. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.
Entries (RSS)